PWM
CNCR

Perigon Wealth Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Perigon Wealth Management’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$32K – 596
2020
Q4 		$32K Buy
+1,000
New +$30K ﹤0.01% 876

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LWPC
Legacy Wealth Partners (California) Calabasas, California $180M AUM 48.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Perigon Wealth Management's CNCR Position: Q1 2021 in Review

Perigon Wealth Management sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2021, closing a stake of 1,000 shares — an estimated $32K sold.

Perigon Wealth Management first reported a position in CNCR in Q4 2020 and held it in 1 quarter. The position peaked at $32K in Q4 2020. 22 funds tracked by Wall St. Rank hold CNCR as of Q1 2021.

  • Perigon Wealth Management reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2021 after selling out during the quarter.
  • Perigon Wealth Management sold 1,000 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2021, an estimated $32K.
  • Perigon Wealth Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2020 and held it in 1 quarter.
  • Perigon Wealth Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $32K in Q4 2020.
  • 22 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2021.

Based on Perigon Wealth Management's 13F filing for Q1 2021, filed 17 May 2021.